Stefan Michiels
Overview
Explore the profile of Stefan Michiels including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
233
Citations
9999
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cabrit N, Cheugoua-Zanetsie M, Tierney J, Thirion P, Nankivell M, Winter K, et al.
Eur J Cancer
. 2025 Feb;
218:115292.
PMID: 39938127
Background: The use of surrogate endpoints may expedite the reporting of study outcomes of clinical trials. The validity of disease-free survival (DFS) as a surrogate for overall survival (OS) in...
2.
Dixon-Douglas J, Virassamy B, Clarke K, Hun M, Luen S, Savas P, et al.
NPJ Breast Cancer
. 2024 Oct;
10(1):94.
PMID: 39433772
The role of adaptive immunity in long-term outcomes in early breast cancer is increasingly recognised. Standard (neo)adjuvant chemotherapy can have adverse effects on immune cells. We conducted a retrospective longitudinal...
3.
Vasseur D, Bigot L, Beshiri K, Florez-Arango J, Facchinetti F, Hollebecque A, et al.
Mol Cancer
. 2024 Oct;
23(1):221.
PMID: 39363320
Background: Understanding the resistance mechanisms of tumor is crucial for advancing cancer therapies. The prospective MATCH-R trial (NCT02517892), led by Gustave Roussy, aimed to characterize resistance mechanisms to cancer treatments...
4.
Soldato D, Vaz-Luis I, Di Meglio A, Jones L, Michiels S
J Clin Oncol
. 2024 Sep;
42(36):4354-4355.
PMID: 39303199
No abstract available.
5.
Facchinetti F, Loriot Y, Braye F, Vasseur D, Bahleda R, Bigot L, et al.
Clin Cancer Res
. 2024 Sep;
30(21):4943-4956.
PMID: 39226398
Purpose: Understanding resistance to selective FGFR inhibitors is crucial to improve the clinical outcomes of patients with FGFR2-driven malignancies. Experimental Design: We analyzed sequential ctDNA, ± whole-exome sequencing, or targeted...
6.
Sablin M, Gestraud P, Jonas S, Lamy C, Lacroix-Triki M, Bachelot T, et al.
Br J Cancer
. 2024 Aug;
131(6):1060-1067.
PMID: 39090361
Background: Copy number alterations (CNA) are acquired during the evolution of cancers from their early stage to metastatic stage. This study aims at analysing the clinical value of the identified...
7.
Rousseau A, Michiels S, Simon-Tillaux N, Lolivier A, Bonastre J, Planchard D, et al.
Lancet Reg Health Eur
. 2024 Jul;
43:100970.
PMID: 39040528
Background: The efficacy of front-line pembrolizumab has been established in studies that limit treatment duration to 2 years, but decision to stop pembrolizumab after 2 years is often at physician's...
8.
Geurts V, Balduzzi S, Steenbruggen T, Linn S, Siesling S, Badve S, et al.
JAMA Oncol
. 2024 Jun;
10(8):1077-1086.
PMID: 38935352
Importance: The absolute benefit of chemotherapy for all patients with stage I triple-negative breast cancer (TNBC) is unclear, and biomarkers are not currently available for selecting patients with an excellent...
9.
Soldato D, Michiels S, Havas J, Di Meglio A, Pagliuca M, Franzoi M, et al.
J Clin Oncol
. 2024 Jun;
42(25):3022-3032.
PMID: 38838281
Purpose: Postdiagnosis exercise is associated with lower breast cancer (BC) mortality but its link with risk of recurrence is less clear. We investigated the impact and dose-response relationship of exercise...
10.
Leon-Ferre R, Jonas S, Salgado R, Loi S, de Jong V, Carter J, et al.
JAMA
. 2024 Apr;
331(13):1135-1144.
PMID: 38563834
Importance: The association of tumor-infiltrating lymphocyte (TIL) abundance in breast cancer tissue with cancer recurrence and death in patients with early-stage triple-negative breast cancer (TNBC) who are not treated with...